Dr Weikert has more than 10 years of experience in the pharmaceutical industry. Prior to founding Inventages, Dr Weikert was a senior vice president and global head for life science deals at Bayer AG. While at Bayer, he oversaw venture investments in technology companies and collaborations representing some of the most significant deals between big-pharma and biotechnology at that time.

Dr. Weikert received his MD from the University of Düsseldorf and his PhD in the field of metabolism from the Diabetes Research Center in Germany. He also holds an MBA.

Mr. Pedersen’s responsibilities included the establishment of Lundbeck in the USA and Japan. Mr Pedersen was with Lundbeck for over 20 years serving in various positions within business development, corporate affairs and commercialization. Mr Pedersen serves as the Executive Chairman of the Board of moksha8; Chairman of the Boards of  x3Capital A/S and Ergolet A/S and Board member of Index Pharmaceuticals AB and Broen-Lab A/S. Mr. Pedersen obtained a Bachelor of Economics degree in 1983 and a Master of Science degree in Economics in 1985, both from the University of Aalborg.

He started his career at IBM moving on to found Zadall Systems (McKesson) and co-found or invest in a number of HealthIT companies including pc/1, PDX, eRx. Mr. Guld manages investments for his investment company, Ladaz Technologies, Inc. and he is currently a Director of the Mark Anthony Group, owner of wineries and brands such as White Claw & Mikes Hard Lemonade; a Director of Prescryptive, a HealthIT SaaS platform designed to massively disrupt drug delivery and improve wellness; and a Director of SecureRF, which develops quantum-resistant, security tools for powering the Internet of Things.